Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

DISEASE CHARACTERISTICS: * Histologically confirmed malignant glioblastoma multiforme, meeting 1 of the following criteria: * Newly diagnosed disease AND meets the following criteria: * Has undergone prior surgery and radiotherapy with concurrent temozolomide * No prior chemotherapy except for concurrent low-dose temozolomide given with radiotherapy * Recurrent or progressive disease after front-line therapy AND meets the following criteria: * No more than 1 prior chemotherapy regimen in the adjuvant setting * More than 4 months since last adjuvant treatment * No prior chemotherapy for recurrence * Bidimensionally measurable disease, defined as ≥ 1 enhancing lesion ≥ 1 cm x 1 cm by CT scan or MRI, within 21 days of study entry (for patients with recurrent/relapsed disease) * Patients receiving steroids must be on stable dose for at least 14 days before baseline CT scan or MRI * Paraffin-embedded sample of primary or metastatic tumor diagnostic specimen must be available PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * Absolute granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 120,000/mm³ * Bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No upper gastrointestinal condition or other condition that would preclude compliance with oral m…